TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06586957: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Sponsor: NiKang Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 238 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT06586957 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06586957 Rescue Dossier →